Celularity Inc. (CELU) Stock

About Celularity Inc.

Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.

Celularity Inc. is led by CEO Robert Joseph Hariri, employs 120 people, headquartered in US, publicly traded since 2019.

Celularity Inc. (CELU) stock trades at $0.98 with a market capitalization of $31.73M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.46, reflecting a net loss over the last twelve months, a negative price-to-book of -1.08, reflecting negative shareholders' equity, price-to-sales of 2.24. Over the past 52 weeks the stock has ranged between $0.56 and $2.55, and currently trades 61.6% below its 52-week high.

On profitability, Celularity Inc. generates a return on equity (ROE) of 239.78% (not meaningful, as shareholders' equity is negative), return on capital employed of -210.94%, an operating margin of -225.93%, a net profit margin of -375.77%.

Official website: www.celularity.com

Celularity Inc. by the numbers, 2018–2025

Between 2018 and 2025 Celularity Inc. reported revenue of $18.0M rising to $27.0M, a change of +50.0% across 8 years. Compounded, revenue has grown 14.0% a year over five years, 14.5% over three, -50.0% over the last twelve months. Net profit was $-92.0M in 2025.

Operating margin went from -0.0% in 2018 to -230.9% in 2025, a fall of 230.9 percentage points. The most recent net margin is -375.77%. On a trailing twelve-month basis to Jun '26, revenue is $18.0M and net profit $-45.0M.

Borrowings stand at $41.0M, cash on hand is $1.0M, cash from operations was $-13.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged -194.9% over five years, and was 242.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Celularity Inc. (CELU) — frequently asked questions